Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NewLink Genetics NLNK

Lumos Pharma Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD).


NDAQ:NLNK - Post by User

<< Previous
Bullboard Posts
Post by Estimator36on May 12, 2015 7:22pm
276 Views
Post# 23721642

Glad

GladGlad I sold out at 42.00. But I think the pancreatic trial is going to succeed. Years ago I was in Lorus Therapeutics (now Aptose) and I made a lot of money going from .34 to 2.50 +. Jim Wright was CEO. NewLink is mirroring them with the exception that NewLink has more enrolled patients (777 I think) which makes a very big difference. This is very risky, but if you can pick up less than 29.00 then I think you can make money. Good luck to all.
<< Previous
Bullboard Posts